Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alicaforsen in Active Crohn's Disease
NCT00048113Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2001
- Primary completion
- Apr 2002
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Alicaforsen with Placebo (2 arms). Primary endpoint: Clinical Remission (CDAI <= 150) at 12 weeks. Started Jan 2001; status: completed.
02
Drugs
alicaforsen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00048113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048113.